Defensible evidence across the pharmaceutical product lifecycle.
We help pharma, biotech, and medical device companies anticipate scrutiny, generate rigorous and decision-relevant evidence, and defend value across health technology assessment submissions, reimbursement decision-making, and post-launch reassessment.
Evidence must withstand scrutiny — methodologically, analytically, and contextually.
Pharmalytics Group is a specialist health technology assessment, health economics and outcomes research, and market access consultancy. Our approach combines advanced methods, disciplined analytical execution, and reimbursement intelligence to ensure evidence remains coherent from early planning through payer review.
End-to-end evidence, engineered to withstand scrutiny.
![[hta]DataMine™ — Powered by Pharmalytics Group Technologies](/__l5e/assets-v1/4448a767-ea0e-4508-ba22-dd45899c9b52/hta-datamine-yellow.png)
Reimbursement decisions leave patterns. We study them.
[hta]DataMine™ is a proprietary HTA intelligence platform that translates reimbursement precedent into actionable insight, benchmarking the evidence drivers that influence reimbursement outcomes and anticipating how evolving data may shape evidence strategy across the product lifecycle.
What clients say.
An important strategic partner in reimbursement. Methodologists who understand the industry exceptionally well.
Planning your evidence strategy?
Bring us in early. We help teams pressure-test their strategy, address critical evidence gaps, and build a defensible evidence package long before a dossier is written.